Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Boehringer Ingelheim
Johnson and Johnson
Baxter
McKinsey

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

DSUVIA Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which patents cover Dsuvia, and when can generic versions of Dsuvia launch?

Dsuvia is a drug marketed by Acelrx Pharms and is included in one NDA. There are sixteen patents protecting this drug.

This drug has eighty-four patent family members in nineteen countries.

The generic ingredient in DSUVIA is sufentanil citrate. There are nine drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the sufentanil citrate profile page.

US ANDA Litigation and Generic Entry Outlook for Dsuvia

A generic version of DSUVIA was approved as sufentanil citrate by WEST-WARD PHARMS INT on January 23rd, 2020.

  Start Trial

Drug patent expirations by year for DSUVIA
Drug Prices for DSUVIA

See drug prices for DSUVIA

Pharmacology for DSUVIA
Drug ClassOpioid Agonist
Mechanism of ActionFull Opioid Agonists
Synonyms for DSUVIA
2-hydroxypropane-1,2,3-tricarboxylic acid;N-[4-(methoxymethyl)-1-(2-thiophen-2-ylethyl)-4-piperidinyl]-N-phenylpropanamide
4073AH
56030-54-7
AB0174863
AFE2YW0IIZ
ARX 04
ARX04
BDBM94503
C08022
C22H30N2O2S
CHEBI:9316
CHEMBL658
Chronogesic
cid_65494
citric acid;N-[4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidyl]-N-phenyl-propionamide
CS-2279
D05938
DB00708
Dsuvia (brand name)
DTXSID6023604
Epitope ID:153513
GGCSSNBKKAUURC-UHFFFAOYSA-N
GTPL3534
HSDB 6760
HY-13754
L000580
LS-175693
N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenylpropanamide
N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)propionanilide
N-(4-(methoxymethyl)-1-(2-(thiophen-2-yl)ethyl)piperidin-4-yl)-N-phenylpropionamide
N-(4-(Methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidinyl)-N-phenylpropanamide #
N-[4-(methoxymethyl)-1-(2-thiophen-2-ylethyl)piperidin-4-yl]-N-phenyl-propanamide;2-oxidanylpropane-1,2,3-tricarboxylic acid
N-[4-(methoxymethyl)-1-(2-thiophen-2-ylethyl)piperidin-4-yl]-N-phenylpropanamide
N-[4-(Methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidinyl]propionalnalide
N-[4-(Methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidyl]propionanilide
N-[4-(methoxymethyl)-1-[2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropanamide
N-[4-(Methoxymethyl)-1-{2-(2-thienyl)ethyl}-4-piperidinyl]-N-phenylpropanamide
N-{4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]piperidin-4-yl}-N-phenylpropanamide
N-{4-[(methyloxy)methyl]-1-[2-(2-thienyl)ethyl]piperidin-4-yl}-N-phenylpropanamide
NCGC00247355-01
Oprea1_120838
Oprea1_246787
PDSP1_001741
PDSP2_001724
Propanamide, N-(4-(methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenyl-
propanamide, N-[4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidinyl]-N-
Propanamide, N-[4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenyl-
Q417915
R 30,730
R 30730
R-30730
SC-39001
SCHEMBL26728
Sufenta (brand name)
SUFENTANIL
Sufentanil (USAN/INN)
Sufentanil [USAN:BAN:INN]
Sufentanil [USAN:INN:BAN]
Sufentanil Base
Sufentanilo
Sufentanilum
Sufentanilum [INN-Latin]
Sufentanyl
Sulfentanil
Sulfentanyl
UNII-AFE2YW0IIZ
Z-3179
Zalviso
ZINC538386

US Patents and Regulatory Information for DSUVIA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Acelrx Pharms DSUVIA sufentanil citrate TABLET;SUBLINGUAL 209128-001 Nov 2, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Acelrx Pharms DSUVIA sufentanil citrate TABLET;SUBLINGUAL 209128-001 Nov 2, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Acelrx Pharms DSUVIA sufentanil citrate TABLET;SUBLINGUAL 209128-001 Nov 2, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for DSUVIA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2114383 122016000023 Germany   Start Trial PRODUCT NAME: SUFENTANIL, WAHLWEISE IN FORM VON SUFENTANILCITRAT; REGISTRATION NO/DATE: EU/1/15/1042 20150918
2114383 CA 2016 00007 Denmark   Start Trial PRODUCT NAME: SUFENTANIL, HERUNDER SUFENTANIL SOM CITRAT; REG. NO/DATE: EU/1/15/1042/001-006 20150922
2114383 16C0010 France   Start Trial PRODUCT NAME: SUFENTANIL; REGISTRATION NO/DATE: EU/1/15/1042 20150918
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Johnson and Johnson
Harvard Business School
Medtronic
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.